
|Videos|January 11, 2016
The Aftermath of Hepatitis C Drugs on Specialty Spending
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
3
New CKD Outcome Set Tells Pharmacists What to Measure
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5



































































































